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Rosuvastatin 10 mg was effective in the reduction of TC in a
Scottish General Practice. The majority of patients were able to
achieve SIGN targets and many patients also achieved the lower
JBS2 targets.
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OBJECTIVES: The All Wales Medicines Strategy Group
(AWMSG) recommends that at risk patients should be treated to
a total cholesterol (TC) target of <5 mmol/L and low density
lipoprotein-cholesterol (LDL-C) <3 mmol/L. Recent Joint British
Societies Guidelines (JBS2, 2005) advise patients be treated to
TC <4 mmol/L and LDL-C <2 mmol/L. An audit was conducted
to determine the effect of the new guidelines on the proportion
of patients achieving target cholesterol levels with rosuvastatin.
METHODS: General Practice records were searched to identify
patients who had been prescribed rosuvastatin 10 mg and the fol-
lowing data recorded: previous statin therapy, last cholesterol
result on that statin and ﬁrst cholesterol test on rosuvastatin.
RESULTS: A total of 337 patients who had been prescribed
rosuvastatin were identiﬁed. Of these 273 patients prescribed
rosuvastatin 10 mg had both a pre- and post-rosuvastatin treat-
ment TC result, 33 had LDL-C results. The majority of patients
were statin-naive (195), others had previously been prescribed
atorvastatin mean dose 18 mg (n = 45), simvastatin mean dose
20 mg (n = 29) or pravastatin mean dose 23 mg (n = 4). Prior to
treatment with rosuvastatin, 11% (29/273) had a TC <5 mmol/L,
increasing to 79% (215/273) after treatment with rosuvastatin
10 mg. On average patients experienced a 1.6 mmol/L (26%)
reduction in TC. The proportion of patients with LDL-C 
<3 mmol/L improved from 12% (4/33) to 94% (31/33) on rosu-
vastatin. On average patients experienced a 1.6 mmol/L (42%)
reduction in LDL-C. Improvements were also seen against JBS2
targets; patients with TC <4 mmol/L improved from 0% prior 
to rosuvastatin to 32% on rosuvastatin 10 mg and similarly
patients with LDL-C <2 mmol/L improved from 0% to 39%.
CONCLUSIONS: Rosuvastatin 10 mg wass effective in the
reduction of TC and LDL-C in a Welsh general practice. The
majority of patients were able to achieve AWMSG targets and
many patients also achieve the recommended lower JBS2 targets.
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OBJECTIVES: To compare the effectiveness of statins in a real
world setting as measured by percentage low density lipoprotein
cholesterol (LDL-C) reduction and percentage total cholesterol
(TC) reduction in patients newly initiated on statin therapy.
METHODS: For this retrospective cohort study, patients newly
initiated on common start doses of statin therapies (rosuvastatin
10 mg, simvastatin 10/20 mg, pravastatin 20/40 mg and atorvas-
tatin 10/20 mg) between January 1, 2003 and August 31, 2005
were identiﬁed from the UK DIN-LINK database. Patients with
no dyslipidemic therapy in the 12 months preceding their initial
statin prescription and an LDL-C or TC measurement less than
6 months before and at least 1 month after initiating statin
therapy were included in the study. Adjusted percent LDL-C
reductions and percent TC reductions were compared using
linear regression techniques. RESULTS: A total of 2151 patients
with complete LDL-C data were identiﬁed. Rosuvastatin (n =
159), atorvastatin (n = 836), simvastatin (n = 1107) and pravas-
tatin (n = 49) groups were similar with respect to mean age (64.5,
64.4, 65.1 and 65.1 years respectively) and baseline LDL-C levels
(4.4, 4.3, 4.3 and 4.0 mmol/L respectively). After adjusting for
age, gender, baseline LDL-C, therapy duration and 2003 Euro-
pean guideline risk factors, patients initiated on rosuvastatin
achieved a signiﬁcantly greater percentage LDL-C reduction
(44.8%; 95% conﬁdence interval 42.1%–47.4%) than patients
initiated on atorvastatin (40.4%; 39.2%–41.5%), simvastatin
(36.5%; 35.5%–37.5%) or pravastatin (29.9%; 25.1%–34.5%):
all p < 0.01. Similarly, in patients where complete TC data was
available (n = 7070), patients initiated on rosuvastatin (n = 475)
had a signiﬁcantly greater adjusted percentage TC reduction
(31.3%; 30.1%–32.5%) than patients initiated on atorvastatin
(n = 2662; 28.2%; 27.7%–28.7%), simvastatin (n = 3665;
25.3%; 24.9%–25.7%) or pravastatin (n = 268; 20.7%;
19.1%–22.3%): all p < 0.0001. CONCLUSIONS: In patients
newly initiated on usual start doses of statins in routine practice,
rosuvastatin was more effective in lowering both LDL-C and TC
than atorvastatin, simvastatin and pravastatin.
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OBJECTIVE: Low adherence to antihypertensive drug (AHT)
treatment may limit patient’s beneﬁts in terms of a reduction of
cardiovascular and cerebrovascular disease. This study investi-
gated the relationship between persistence with antihypertensive
drugs and risk of myocardial infarction (MI) or stroke in daily
practice. METHODS: From the PHARMO record linkage
system comprising, among other medical information, the med-
ication histories and hospital discharge diagnoses of >2 million
inhabitants in The Netherlands, new users of AHT were identi-
ﬁed between 1993–2002. Persistence with AHT was determined
by summing the number of days of continuous treatment (gaps
between dispensings <60 days). Persistent patients remained on
AHT for 24 months. The outcome of interest was the ﬁrst hos-
pital admission for MI or stroke occurring two or more years
after initiation of AHT therapy. Patients were classiﬁed at high,
intermediate or low cardiovascular risk based on other cardio-
vascular drug use and hospitalizations during the ﬁrst two years
of follow-up. RESULTS: The study included 98,485 patients of
whom 16% were at high cardiovascular risk. About 50% (n =
48,548) of all patients were persistent with AHT for two years.
Multivariate analyses showed that persistent users of AHT had
a statistically signiﬁcant lower risk for MI/stroke compared to
non-persistent users (RRadj = 0.88; 95%CI: 0.82–0.94). The
association was stronger in the low/intermediate risk group
(RRadj = 0.85; 95%CI: 0.79–0.92) than in the high risk group
(RRadj = 0.95; 95%CI: 0.83–1.09). CONCLUSION: Non-
persistent use of AHT in daily practice leads to increased risk of
hospitalizations for MI or stroke.
